Compare BCO & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCO | ABCL |
|---|---|---|
| Founded | 1859 | 2012 |
| Country | United States | Canada |
| Employees | 125 | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.1B |
| IPO Year | 2010 | 2020 |
| Metric | BCO | ABCL |
|---|---|---|
| Price | $116.78 | $11.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $145.33 | $18.00 |
| AVG Volume (30 Days) | 506.8K | ★ 3.2M |
| Earning Date | 11-04-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.87% | N/A |
| EPS Growth | ★ 29.20 | 10.91 |
| EPS | ★ 2.19 | N/A |
| Revenue | ★ $3,562,300,000.00 | $75,128,000.00 |
| Revenue This Year | $5.10 | N/A |
| Revenue Next Year | $3.37 | $10.03 |
| P/E Ratio | $53.34 | ★ N/A |
| Revenue Growth | N/A | ★ 160.56 |
| 52 Week Low | $91.05 | $2.75 |
| 52 Week High | $136.37 | $14.98 |
| Indicator | BCO | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 63.86 | 45.51 |
| Support Level | $107.15 | $10.65 |
| Resistance Level | $124.32 | $13.21 |
| Average True Range (ATR) | 5.15 | 1.00 |
| MACD | 1.06 | -0.06 |
| Stochastic Oscillator | 84.91 | 25.16 |
The Brink's Co is a provider of secure logistics and security solutions for cash and other valuables. Its segments include: North America segment includes operations in the U.S. and Canada, including the Brink's Global Services (BGS) line of business; Latin America segment consists operations in Latin American countries where it has an ownership interest, including the BGS line of business; Europe segment includes total operations in European countries that provide services outside of the BGS line of business; and Rest of World segment consists operations in the Middle East, Africa and Asia. It also includes total operations in European countries that provide BGS services and BGS activity in Latin American countries. It derives maximum revenue from the North America segment.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.